Heart Failure Collaboratory Statement on Clinical Trials in the Landscape of COVID-19

JACC: Heart Failure

Abraham, William T.; Fiuzat, Mona; Psotka, Mitchell A.; O’Connor, Christopher M.

Introduction

Heart Failure Collaboratory Statement on Clinical Trials in the Landscape of COVID-19 The COVID-19 pandemic has disrupted health care delivery systems around the world, with a significant impact on clinical trials for current and future study participants, sponsors, investigators, coordinators, and regulators. Thoughtful consideration on how to manage clinical trials during the COVID-19 pandemic is of particular relevance to the heart failure (HF) ecosystem, as HF patients represent a vulnerable population at high risk for COVID-19 related morbidity and mortality. This ecosystem includes patients with HF, clinical trialists, investigators, research coordinators, regulatory authorities, payers, and both public and private sponsors of HF clinical trials.

Keywords

Clinical aspects, diagnosis, treatment